|Status : Published||Published On : Mar, 2022||Report Code : VRHC1259||Industry : Healthcare||Available Format :||Page : 200|
The global viral and non-viral vector manufacturing market is anticipated to grow from USD 1.6 billion in 2022 to USD 24.3 billion by 2030, registering a CAGR of 18.45% during the forecast period 2023-2030. Innovative therapies that involve vectors, such as gene therapy and cell therapy, have had a tremendous impact on medicine in the last few decades. Therapies that require genetic modification, such as the introduction of therapeutic deoxyribonucleic acid (DNA)/gene into a patient's body or cell, have shown significant impact in the treatment of a variety of fatal diseases, including cancer, Alzheimer's disease, Parkinson's disease, and rheumatoid arthritis, etc. The creation and standardization of numerous viral and non-viral vectors to meet unmet medical needs have been emphasized in light of the promising outcomes shown by these vector-based therapeutics in several preclinical and clinical investigations.
The viral vector and non-viral manufacturing industries are projected to benefit from the COVID-19 epidemic. there are many COVID-19 vaccine candidates which have entered into clinical trials and including viral vector vaccines. These vaccines are very likely to be among the COVID-19 vaccines that have been approved for use worldwide.
Insight by Vector Type
Based on vector type, the global viral and non-viral vector manufacturing market is segmented into viral vector and non-viral vectors. The viral vector is further divided into Adenoviral Vector, Retroviral Vector, Adeno-Associated Viral Vector, Lentiviral Vector, Vaccinia Viral Vector, and Other Viral Vectors. The non-viral vector is further divided into Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, and Other Non-Viral Vectors. Because of the ease of application in major target diseases such as cancer and genetic disorders, the retroviral vectors segment dominated the market.
Insight by Disease
Based on disease, the global viral and non-viral vector manufacturing market is classified into cancer, genetic disease, infectious disease, cardiovascular disease, and other diseases. The cancer segment is anticipated to contribute to the largest share during the forecast period owing to the rising number of clinical trials and availability of approved viral vector-based cancer drugs. Furthermore, the rising number of patients suffering from cancer and modern healthcare facilities will propel the growth of the market.
The genetic disorders segment is anticipated to grow at a faster pace during the forecast period owing to the rising number of research activities like hemophilla A & B, Huntington’s disease, sickle cell anemia, etc. and a robust genetic therapy pipeline will accelerate the growth of the market.
Insight by Application
Based on application, the global viral and non-viral vector manufacturing market is divided into gene therapy, vaccinology, cell therapy, and others. Gene therapy is anticipated to witness the largest share in the market owing to the rising number of gene therapy clinical trials for chronic and infectious diseases like cancer, cardiovascular diseases, and neurodegenerative diseases globally.
Viral and Non-Viral Vector Manufacturing Market Report Coverage
Base Year Considered
Market Size in 2021
Revenue Forecast in 2027
Segments Covered in the Report
By Vector Type, By Disease, and By Application
Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Impact of COVID-19; Companies’ Strategic Developments; Market Share Analysis of Key Players; Company Profiling
Regions Covered in the Report
North America, Europe, Asia-Pacific, Middle East, and Rest of the World
Viral vectors and non-viral vectors have attracted substantial global attention as a potential therapeutic method to treat a wide variety of severe diseases, resulting in increased investments in drug research and commercialization. The global viral and non-viral vector manufacturing market is growing due to the increasing popularity of gene and cell therapy products (which use vectors), increased adoption of nucleic acid therapeutics in non-viral vectors, mounting synergistic activities, and increased funding activities supporting vector-based therapeutic research will bolster the growth of the market. Furthermore, rising rates of genetic abnormalities, cancer, and deadly diseases, as well as an expanding number of clinical trials and a solid pipeline of gene and cell therapy products along with vector-based vaccines, are all driving factors for market expansion.
The challenges faced by the viral and non-viral vector manufacturing market include massive cost involved in gene therapy, surging manufacturing cost of viral vectors, complications involved in large scale production of viral vectors along with low transfection efficiency for non-viral vectors might impede the growth of the market.
The rapid rise in genetically modified therapies, increased demand for synthetic genes along the advent of next-generation vectors has resulted in a significant increase in demand for various vectors for basic and pharmacological research, creating opportunities for companies with expertise in targeted gene delivery.
North America contributes the largest share in the viral and non-viral vector manufacturing market owing to the increased implementation of viral vector-based gene therapies to treat chronic and rare diseases, rising number of regenerative medicine companies, availability of funds along with the availability of FDA approved gene therapies, thereby bolstering the growth in the region.
The global viral and non-viral vector manufacturing market is made up of both established and new companies. Several companies are attempting to enter the market and maintain competition by attempting to launch new manufacturing capacities, expanding their businesses, collaborating with viral and non-viral vector manufacturing companies to innovate new cell therapies, and vaccines for several diseases, or developing proprietary viral and non-viral vector platforms.
Catalent Cell & Gene Therapy is a technology, development, and manufacturing partner for breakthrough therapies that leads the industry. Its extensive cell therapy portfolio includes expertise in a wide range of cell types, which include CAR-T, TCR, TILs, NKs, iPSCs, and MSCs. Catalent is a full-service partner for plasmid DNA, adeno-associated viral (AAV), lentiviral and other viral vectors, oncolytic viruses, and live virus vaccines, with strong knowledge in viral vector discovery, scale-up, and production for gene treatments.
GenScript creates a GMP platform for vector production, including viral and non-viral vectors. Gene and cell therapy (GCT) has the potential to revolutionize medicine by offering long-term and perhaps curative treatment options for a variety of disorders. Plasmids and viruses in various quality levels are offered as part of the new medication development process to meet requirements at various stages with a quick turnaround time.
In October 2021, Boehringer Ingelheim, IP Group, the UK Cystic Fibrosis Gene Therapy Consortium, and Oxford Biomedica (OXB) stated that Boehringer Ingelheim has exercised its options on intellectual property and know-how from the partners in order to advance and accelerate the development of a potential new treatment option for CF patients. In the partnership, IP Group grants exclusive global rights to develop, manufacture, register, and commercialize this lentiviral vector-based gene therapy for the treatment of cystic fibrosis on behalf of the three GTC host universities. The GTC also contributes expertise in pre-clinical research and clinical gene therapy development. OXB is complementing Boehringer Ingelheim's expertise in the development of novel breakthrough therapies for respiratory diseases with its leading expertise in manufacturing lentiviral vector-based therapies.
In October 2021, Catalent, one of the prominent leaders in facilitating biopharma, cell, gene, and consumer health partners to significantly improve the development, launch, and supply of better patient treatments across multiple modalities, has announced a $230 million expansion project at its gene therapy campus in Harmans, Maryland, resulting in adding three more commercial-scale viral vector manufacturing suites, as well as associated support facilities and services, to meet growing customer demand.
Some of the industry players in the global viral and non-viral vector manufacturing market include Boehringer Ingelheim International GmbH, Catalent, Inc, GenScript ProBio, Lonza, Merck KGaA, Oxford Biomedica, Sartorius AG, Takara Bio Inc., Thermo Fisher Scientific Inc., and Evonik Industries AG.
The Viral and Non-Viral Vector Manufacturing Market report offers a comprehensive market segmentation analysis along with an estimation for the forecast period 2021–2027.
Segments Covered in the Report
Region Covered in the Report
To explore more about this report - Request a free sample copy
The Viral and Non-Viral Vector Manufacturing Market report offers a comprehensive market segmentation analysis along with an estimation for the forecast period 2023–2030.
Segments Covered in the Report
• By Vector Type
- Viral Vector
> Adenoviral Vector
> Retroviral Vector
> Adeno-Associated Viral Vector
> Lentiviral Vector
> Vaccinia Viral Vector
> Other Viral Vector
- Non-Viral Vector
> Plasmid DNA
> Lipid-Based Non-Viral Vector
> Polymer-Based Non-Viral Vector
> Other Non-Viral Vector
• By Disease
- Genetic Disease
- Infectious Disease
- Cardiovascular Disease
- Other Diseases
• By Application
- Gene Therapy
- Cell Therapy
Region Covered in the Report
• North America
- Rest of Europe
• Asia-Pacific (APAC)
- South Korea
- Rest of Asia-Pacific
• Rest of the World (RoW)
- Saudi Arabia
- South Africa
- Other Countries